Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis

• Published in: European urology 2017-04, Vol.71 (4), p.570-581
• Main Authors: Dahm, Philipp, Brasure, Michelle, MacDonald, Roderick, Olson, Carin M, Nelson, Victoria A, Fink, Howard A, Rwabasonga, Bruce, Risk, Michael C, Wilt, Timothy J
• Format: Article
• Language: English
• Subjects: 5-alpha reductase inhibitor; 5-alpha Reductase Inhibitors - therapeutic use; Adrenergic alpha-Antagonists - therapeutic use; Adrenergic beta-3 Receptor Agonists - therapeutic use; Alpha blockers; Benign prostatic hyperplasia; Comparative effectiveness; Comparative Effectiveness Research; Drug Therapy, Combination; Humans; Lower urinary tract symptoms; Lower Urinary Tract Symptoms - drug therapy; Lower Urinary Tract Symptoms - etiology; Male; Muscarinic Antagonists - therapeutic use; Phosphodiesterase 5 Inhibitors - therapeutic use; Prostatic Hyperplasia - complications; Prostatic Hyperplasia - drug therapy; Randomized trials; Systematic review; Treatment Outcome; Urology
• ISSN: 0302-2838; 1873-7560
• DOI: 10.1016/j.eururo.2016.09.032

Abstract Context Alpha-blockers (ABs) and 5-alpha reductase inhibitors have an established role in treating male lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH). Recently, newer drugs have shown promise for this indication. Objective To assess the comparative effectiveness and adverse effects (AEs) of newer drugs to treat LUTS attributed to BPH through a systematic review and meta-analysis. Evidence acquisition Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and Ovid Embase bibliographic databases (through June 2016) were hand searches for references of relevant studies. Eligible studies included randomized controlled trials published in English of newer ABs, antimuscarinics, a beta-3 adrenoceptor agonist, phosphodiesterase type-5 inhibitors, or combination therapy with one of these medications as an active comparator. Observational studies of the same agents with a duration ≥1 yr that reported AEs were also included. Evidence synthesis We synthesized evidence from 43 randomized controlled trials as well as five observational studies. Based on improvement of mean International Prostate Symptom Score and quality of life scores, the effectiveness of the newer ABs was not different from the older ABs (moderate strength of evidence [SOE]), but had more AEs (low SOE). Antimuscarinics/AB combination therapy had similar outcomes as AB monotherapy (all moderate SOE), but often had more AEs. Phosphodiesterase type-5 inhibitors alone or in combination with ABs had similar or inferior outcomes than ABs alone. Evidence was insufficient for the beta-3 adrenoceptor agonist. For all newer agents, the evidence was generally insufficient to assess long-term efficacy, prevention of symptom progression, or AEs. Conclusions None of the drugs or drug combinations newly used to treat LUTS attributed to BPH showed outcomes superior to traditional AB treatment. Given the lack of superior outcomes, the studies’ short time-horizon, and less assurance of their safety, their current value in treating LUTS attributable to BPH appears low. Patient summary In this paper, we reviewed the evidence of newer drugs to treat men with urinary problems attributable to an enlarged prostate. We found none of the new drugs to be better but there was more concern about side effects.